In a revealing preclinical research, the weight-loss drug tirzepatide—already identified for combating weight problems and diabetes—unexpectedly slowed the expansion of breast most cancers tumors in overweight mice.
Researchers discovered that because the mice shed fats, their tumors shrank too, suggesting a direct hyperlink between weight reduction and lowered most cancers development.
Promising Weight problems Drug Curbs Breast Most cancers in Mice
A current research offered at ENDO 2025, the annual assembly of the Endocrine Society in San Francisco, Calif., discovered that tirzepatide, a medicine accredited for kind 2 diabetes beneath the model identify Mounjaro and for weight reduction as Zepbound, slowed the expansion of breast most cancers linked to weight problems in a mouse mannequin.
“Weight problems is a major danger issue for breast most cancers, and whereas it is vitally preliminary information, our research in mice recommend that these new anti-obesity medication could also be a approach to scale back obesity-associated breast most cancers danger or enhance outcomes,” stated research writer Amanda Kucinskas, B.S., a Ph.D. candidate within the labs of Drs. Erin Giles and Kanakadurga Singer on the College of Michigan in Ann Arbor, Mich.
Challenges of Conventional Weight Loss for Most cancers Prevention
Scientists have lengthy identified that weight problems can result in worse outcomes for folks with breast most cancers, whereas weight reduction has been related to higher prognoses. Nonetheless, attaining and sustaining weight reduction by means of typical strategies stays tough for a lot of people.
To discover alternate options, Kucinskas and her workforce turned to tirzepatide. This treatment belongs to a brand new class of medication that activate each GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide) receptors, that are concerned in regulating blood sugar and urge for food. The researchers aimed to find out whether or not this drug might additionally gradual the development of breast most cancers tied to weight problems.
Contained in the Mouse Research Design
This mouse research included 16 mice. The 9-week-old C57BL/6 mice had been fed a 40% high-fat weight-reduction plan and housed in a heat setting to induce weight problems. At 32 weeks of age, the mice with weight problems had been randomly assigned injections of tirzepatide or a placebo each different day for 16 weeks. Tumor volumes had been measured twice weekly.
The researchers discovered that the anti-obesity drug lowered physique weight and physique fats by roughly 20% in mice, just like the quantity of weight reduction achieved by ladies on this drug. They discovered this was primarily on account of a lack of adipose mass, with a discount in adipose depot weights in comparison with controls.
Correlating Physique Weight With Tumor Development
The anti-obesity drug additionally lowered tumor quantity in comparison with the controls. On the finish of the research, the researchers discovered that tumor quantity was considerably correlated with physique weight, complete adipose mass and the quantity of fats saved within the liver.
“Whereas these are very preliminary outcomes, they recommend that this new anti-obesity drug can also have a helpful affect on breast most cancers outcomes,” Kucinskas stated.
Ongoing research are underway in collaboration with Dr. Steve Hursting’s lab on the College of North Carolina at Chapel Hill to separate the burden loss from the tumor-specific results of tirzepatide.
Assembly: ENDO 2025
By no means miss a breakthrough: Join the SciTechDaily newsletter.